Nonetheless, our results support the evidence that in STEMI patients, IGFBP-4 is associated with an increased risk of adverse events during long term follow-up and favor the hypothesis that its prognostic ability is notable in patients in the acute phase of a myocardial infarction, even in the contemporary setting of routine primary PCI. Here, IGFBP4 is linked to myocardial infarction.